Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 23
- 13F valueReported value at the end of Q2 2026
- $89.3K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CLDI, Q2 2026
No superinvestor reported holding CLDI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Calidi Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2025 (view filing) | Dec 12 | 4 days | Camaisa AllanDirector | SSale | −850 | $1.46 | −$1.24K | −1.1%77.0K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Schoeneck James ADirector | PPurchase | +75.0K | $2.00 | +$150.0K | +6,613.8%76.1K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Schoeneck James ADirector | PPurchase | +75.0K | – | – | –75.0K after | Derivative |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Poma Eric EChief Executive Officer | PPurchase | +25.0K | $2.00 | +$50.0K | New position25.0K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Poma Eric EChief Executive Officer | PPurchase | +25.0K | – | – | –25.0K after | Derivative |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Leftwich ScottDirector | PPurchase | +125.0K | $2.00 | +$250.0K | +2,212.4%130.7K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Leftwich ScottDirector | PPurchase | +125.0K | – | – | –125.0K after | Derivative |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Jackson Andrew C.Chief Financial Officer | PPurchase | +2.50K | $2.00 | +$5.00K | New position2.50K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Jackson Andrew C.Chief Financial Officer | PPurchase | +2.50K | – | – | –2.50K after | Derivative |
| Dec 18, 2024 (view filing) | Dec 17 | 1 day | Camaisa AllanCEO and Chairman of the Board | SSale | −10.0K | $1.62 | −$16.2K | −13.0%66.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Calidi Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 114,550 | $19.5K | 0.00% | +51,531+81.8% | Added |
| HighTower Advisors, LLC | 83,523 | $14.2K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 54,274 | $9.23K | 0.00% | +19,472+56.0% | Added |
| Independent Advisor Alliance | 45,000 | $7.65K | 0.00% | +45,000 | New |
| RS Crum Inc. | 43,239 | $7.35K | 0.00% | +2,983+7.4% | Added |
| SRS Capital Advisors, Inc. | 37,345 | $6.35K | 0.00% | 00.0% | Unchanged |
| Private Advisor Group, LLC | 30,000 | $5.10K | 0.00% | +30,000 | New |
| Vanguard Capital Management LLC | 25,509 | $4.34K | 0.00% | 00.0% | Unchanged |
| Belpointe Asset Management LLC | 19,921 | $3.39K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 17,758 | $3.02K | 0.00% | 00.0% | Unchanged |